Pinheiro-Barbosa Raquel, Cissé Cheick, Bastos Paulo, Leung Clémence, Traon Anne Pavy-le, Kermorgant Marc, Bonneville Fabrice, Renaud Mathilde, Bonnet Cecile, Wandzel Marion, Roth Virginie, Rascol Olivier, Ory-Magne Fabienne, Fabbri Margherita
Neurology Department University Hospital of Toulouse, Clinical Investigation Center CIC 1436, Parkinson Expert Centre, NeuroToul Center of Excellence in Neurodegeneration (COEN) of Toulouse, CHU of Toulouse, Inserm, University of Toulouse 3, Toulouse, France.
University of Sciences Techniques and Technology of Bamako, Bamako, Mali.
J Neurol. 2024 Dec 12;272(1):45. doi: 10.1007/s00415-024-12738-x.
Spinocerebellar ataxia 27B is the most common genetic late onset cerebellar ataxia (LOCA). However, it commonly overlaps with other genetic LOCA as with the cerebellar form of multiple system atrophy (MSA-C).
To pinpoint which clinical signs and symptoms best discriminate between FGF14 + from FGF14 - patients at symptoms' onset.
Twenty SCA27B (≥ 250 GAA repeat expansion) patients were retrospectively matched by gender and age at disease onset with 20 negative FGF14 (-) LOCA patients and with 20 MSA-C patients. Clinical features were ranked based on their contribution towards distinguishing between the groups (feature importance ranking).
SCA27B patients had significantly higher rates of episodic symptoms, cerebellar oculomotor signs, dysdiadochokinesia, and alcohol intolerance than LOCA-FGF14 - ataxia patients. The lack of autonomic symptoms and MRI signs in SCA27B patients were the most discriminating features from MSA-C. An AUC of 0.87 was obtained if using the "top 3 clinical features model" (episodic symptoms, cerebellar oculomotor signs and dysdiadochokinesia) to distinguish SCAB27 from LCOA FGF14 - . Regarding MRI findings, no significant differences were found between SCA27B and FGF14 - patients, while a positive hot cross buns sign and the presence of brainstem atrophy were key distinguishing features between SCA27B from MSA-C patients (p < 0.005).
Our pilot case-control study contributes to the identification of early clinical symptoms to differentiate SCA27B to LOCA patients including FGF14- and MSA-C ones. From a feature perspective, while clinical features are crucial, identifying surrogate biomarkers-such as ocular or gait parameters-could aid in the early diagnosis and follow-up of SCA27B patients.
脊髓小脑共济失调27B型是最常见的遗传性迟发性小脑共济失调(LOCA)。然而,它通常与其他遗传性LOCA重叠,如多系统萎缩的小脑型(MSA-C)。
确定哪些临床体征和症状能在症状出现时最好地区分FGF14阳性和FGF14阴性患者。
回顾性选取20例脊髓小脑共济失调27B型(≥250个GAA重复扩增)患者,在疾病发作时按性别和年龄与20例FGF14阴性的LOCA患者以及20例MSA-C患者进行匹配。根据临床特征对区分各组的贡献程度进行排序(特征重要性排名)。
与FGF14阴性的LOCA共济失调患者相比,脊髓小脑共济失调27B型患者发作性症状、小脑动眼神经体征、轮替运动障碍和酒精不耐受的发生率显著更高。脊髓小脑共济失调27B型患者缺乏自主神经症状和MRI体征是与MSA-C最具鉴别性的特征。如果使用“前3种临床特征模型”(发作性症状、小脑动眼神经体征和轮替运动障碍)来区分脊髓小脑共济失调27B型和FGF14阴性的LOCA,曲线下面积(AUC)为0.87。关于MRI表现,脊髓小脑共济失调27B型患者和FGF14阴性患者之间未发现显著差异,而阳性的“热十字面包征”和脑干萎缩的存在是脊髓小脑共济失调27B型患者与MSA-C患者之间的关键鉴别特征(p<0.005)。
我们的初步病例对照研究有助于识别早期临床症状,以区分脊髓小脑共济失调27B型与包括FGF14阴性和MSA-C在内的LOCA患者。从特征角度来看,虽然临床特征至关重要,但识别替代生物标志物,如眼部或步态参数,可能有助于脊髓小脑共济失调27B型患者的早期诊断和随访。